About Us Offices Careers
Practice Areas Industry Teams People Insights
Practice Areas Industry Teams People Insights
About Us Offices Careers
Home Insights House Quoted in Law360 About 2020 Whistleblower Developments
See Insights
PDF

House Quoted in Law360 About 2020 Whistleblower Developments

09 September 2020 Law360 News
Partner Bryan House was quoted in the Law360 article, “Whistleblower Developments To Watch For As 2020 Wraps,” which looks at developments this year that might impact whistleblowers.
 
The SEC is preparing to vote on a rule that would give the agency discretion to cut down whistleblower awards in cases yielding $100 million or more in sanctions and have at least a $30 million bounty.
 
Although awards of that magnitude are few and far between, regulators say the new measures would allow the agency to ensure that awards do not "exceed an amount that is reasonably necessary to reward the whistleblower and to incentivize other similarly situated whistleblowers."
 
House said he questioned whether the limits would have much of an impact on whistleblowers or the program.  "I don't think that cutting back the size of the awards undercuts the program," he said.  "It's still a lot of money."
 
If passed, the proposed rule could also give the agency the discretion to adjust upward the smallest awards, those under $2 million, under which a majority of awards fall. House, who defends companies facing whistleblower claims, said this small award provision shows that the proposed rule is not one-sided or detrimental to the program.

People

Bryan B. House
Partner

Related Services

Practice Areas
Securities Enforcement & Litigation Litigation False Claims Act

Insights

Bank of Spain issues registration guidelines for VASPs (Virtual Currency Services Providers)!
26 October 2021
Internet, IT & e-Discovery Blog
Texas Executive Order to Prohibit COVID-19 Vaccine Mandate
26 October 2021
Coronavirus Resource Center:Back to Business
Foley Weekly Automotive Report
26 October 2021
Dashboard Insights
FDA Calls for Repeating Clinical and Bioanalytical Studies
26 October 2021
Health Care Law Today